Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04868799
Status:
COMPLETED
Last Update Posted:
2023-11-28
First Post:
2021-04-29
Brief Title:
Finding New Targets by Proteomic Approaches InnovRT1
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Heterogeneity in Rhabdoid Tumors Proteomic and Single-Cell Analyses to Identify New Therapeutic Targets
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
InnovRT1
Brief Summary:
The investigators aim to explore the inter tumor heterogeneity by a proteomic approach of a wide series of rhabdoid tumors from both intra and extra cranial origins
Detailed Description:
Context Rhaboid tumors RT are aggressive cancers of young infants exposed to the toxicity of heavy treatments often ineffective which justifies the need to identify new treatment strategies These tumors are characterized by the biallelic alteration of SMARCB1 gene encoding one of the subunits of the SWISNF complex a chromatin remodeler These mutations are the only ones found in these very stable cancers which offers few therapeutic targets that can be identified by genomic techniques They are morphologically undifferentiated and pluriphenotypic suggesting the existence of a cellular diversity still poorly described To advance on these questions the investigators laboratory has developed a model of genetically engineered mouse model spontaneously developing RT biologically very similar to their human counterparts
Objectives and methods The investigators project aims to describe the proteomic and phosphoproteomic signatures of these tumors so far described at the genome and transcriptome level an integration of these pangenomic pan-proteomic studies will reveal the most relevant features to target The investigators will fully characterize the proteomic and phosphoproteomic landscape using mass spectrometry on a cohort of clinically radiologically and histopathologically annoted ATRT for which methylome and RNAseq profiling will also be done The investigators will describe the proteomic features of each molecularly defined subgroups and aim to correlate RNAseq changes with proteomic features
Patients will be included if they or their legal representative have given a consent to such a study and if frozen material is stored at Necker Hospital
Expected results This analysis helps to identify how to articulate several innovative therapeutic approaches taking into account both the diversity of the cells to be treated and the real targets proteins to inhibit or restore
Objectives and methods The investigators project aims to describe the proteomic and phosphoproteomic signatures of these tumors so far described at the genome and transcriptome level an integration of these pangenomic pan-proteomic studies will reveal the most relevant features to target The investigators will fully characterize the proteomic and phosphoproteomic landscape using mass spectrometry on a cohort of clinically radiologically and histopathologically annoted ATRT for which methylome and RNAseq profiling will also be done The investigators will describe the proteomic features of each molecularly defined subgroups and aim to correlate RNAseq changes with proteomic features
Patients will be included if they or their legal representative have given a consent to such a study and if frozen material is stored at Necker Hospital
Expected results This analysis helps to identify how to articulate several innovative therapeutic approaches taking into account both the diversity of the cells to be treated and the real targets proteins to inhibit or restore
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None